EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

The future for treatment by bone marrow transplantation for adrenoleukodystrophy, metachromatic leukodystrophy, globoid cell leukodystrophy and Hurler syndrome



The future for treatment by bone marrow transplantation for adrenoleukodystrophy, metachromatic leukodystrophy, globoid cell leukodystrophy and Hurler syndrome



Journal of Inherited Metabolic Disease 18(4): 398-412



Within the past decade, bone marrow transplantation has been applied to over 200 patients worldwide with the intention of treating storage diseases. Bone marrow transplantation has provided a method for treatment of adrenoleukodystrophy, metachromatic leukodystrophy, globoid cell leukodystrophy and Hurler syndrome. After engraftment, significant improvement in the clinical course of each of these diseases occurs. Survival data of engrafted patients are superior to those of non-transplanted. Engraftment and the resulting enzymatic reconstitution are concordant. Outcomes based on neuropsychological tests indicate continued maintenance and in some cases increase in cognitive function. Magnetic resonance imaging as well as spectroscopic examinations of the brain provide further evidence that positive changes occur in the central nervous system following long-term engraftment. A better quality of life follows engraftment. Greater gains from use of bone marrow transplantation for these particular storage diseases will occur in the future. Earlier diagnosis will allow bone marrow transplantation in the presymptomatic stage at a younger age, providing an enhancement of positive effects noted from such treatment. At the same time, advances in bone marrow technology will serve to reduce the risk factors involved with the bone marrow transplantation process itself. These two factors taken together will be more than additive in providing benefits from use of bone marrow transplantation.

(PDF emailed within 0-6 h: $19.90)

Accession: 009580230

Download citation: RISBibTeXText

PMID: 7494399

DOI: 10.1007/bf00710052



Related references

Bone marrow transplantation for globoid cell leukodystrophy, adrenoleukodystrophy, metachromatic leukodystrophy, and Hurler syndrome. Current Opinion in Hematology 6(6): 377-382, 1999

Bone marrow transplantation as effective treatment of central nervous system disease in globoid cell leukodystrophy, metachromatic leukodystrophy, adrenoleukodystrophy, mannosidosis, fucosidosis, aspartylglucosaminuria, Hurler, Maroteaux-Lamy, and Sly syndromes, and Gaucher disease type III. Current Opinion in Neurology 12(2): 167-176, 1999

Hematopoietic stem cell gene therapy in Hurler syndrome, globoid cell leukodystrophy, metachromatic leukodystrophy and X-adrenoleukodystrophy. Current Opinion in Molecular Therapeutics 10(5): 471-478, 2008

Neurological outcomes after hematopoietic stem cell transplantation for cerebral X-linked adrenoleukodystrophy, late onset metachromatic leukodystrophy and Hurler syndrome. Arquivos de Neuro-Psiquiatria 74(12): 953-966, 2017

Measurements from normal umbilical cord blood of four lysosomal enzymatic activities: alpha-L-iduronidase (Hurler), galactocerebrosidase (globoid cell leukodystrophy), arylsulfatase A (metachromatic leukodystrophy), arylsulfatase B (Maroteaux-Lamy). Bone Marrow Transplantation 25(5): 541-544, 2000

Biochemical pathogenesis of genetic leukodystrophies: comparison of metachromatic leukodystrophy and globoid cell leukodystrophy (Krabbe's disease). Neuropediatrics 15 Suppl: 32-36, 1984

Metabolism of cerebroside sulfate and subcellular distribution of its metabolites in cultured skin fibroblasts from controls, metachromatic leukodystrophy, and globoid cell leukodystrophy. Journal of Clinical Investigation 81(2): 310-317, 1988

Metabolism of cerebroside sulfate and subcellular distribution of its metabolites in cultured skin fibroblasts derived form controls metachromatic leukodystrophy globoid cell leukodystrophy and farber disease. Journal of Inherited Metabolic Disease 10(3): 293-296, 1987

Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy and Hurler syndrome. Bone Marrow Transplantation 30(4): 215-222, August, 2002

Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH). Bone Marrow Transplantation 30(4): 215-222, 2002

Engraftment following in utero bone marrow transplantation for globoid cell leukodystrophy. Bone: 399-402, 1997

Metachromatic leukodystrophy partial treatment through bone marrow transplantation. Annals of Neurology 16(3): 399, 1984

Allogeneic bone marrow transplantation for infantile globoid-cell leukodystrophy (Krabbe's disease). Pediatric Transplantation 6(5): 427-431, 2002

Treatment of late infantile metachromatic leukodystrophy by bone marrow transplantation. New England Journal of Medicine 322(1): 28-32, 1990

Treatment of metachromatic leukodystrophy mld with partially matched bone marrow transplantation bmt. Pediatric Research 31(4 PART 2): 140A, 1992